Using the user-provided base rate (NDA ~85%), this application screens as above-average probability because it is a *new formulation* of an already well-characterized, widely used F-18 PSMA PET agent rather than a novel mechanism. FDA accepted Lantheus/Aphelion’s NDA and set a PDUFA goal date of March 6, 2026, implying the file is sufficiently complete for substantive review and not obviously derailed by early deficiencies. ([investor.lantheus.com](https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-acceptance-nda-new-formulation-market?utm_source=openai)) Clinically, PSMA PET meaningfully affects prostate cancer staging/recurrence localization, and piflufolastat F 18 (PYLARIFY) has demonstrated high confirmation rates in recurrent-disease settings with a generally mild AE profile (e.g., headache, dysgeusia, fatigue) and expected class risks (radiation, hypersensitivity, image misinterpretation). ([fda.gov](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer?utm_source=openai)) A formulation intended to increase batch size/supply resilience is aligned with real-world access needs and typically relies heavily on comparability/CMC plus bridging rather than de novo efficacy. Key downside risk is therefore predominantly CMC: higher radioactive concentration can raise radiolysis/stability, sterility assurance, release-specification, and manufacturing control questions—common reasons for CRLs in radiopharmaceuticals. Offsetting that, Lantheus has a strong regulatory/manufacturing track record in this exact product class (PYLARIFY FDA approval in 2021; extensive real-world utilization; ex-U.S. approvals/marketing as PYLCLARI in the EU), which reduces execution risk. ([fda.gov](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer?utm_source=openai)) The PSMA PET landscape is competitive (e.g., Ga-68 PSMA kits like Illuccix/Locametz and other F-18 agents), but competition generally doesn’t drive rejection when benefit-risk is established; it more often pressures differentiation and supply. ([ir.telixpharma.com](https://ir.telixpharma.com/news-releases/news-release-details/illuccix-approved-us-patient-selection-pre-taxane-rlt?utm_source=openai)) Net: unless FDA identifies a material manufacturing/stability gap, approval is the most likely outcome by the March 6, 2026 action date.

The FDA approved Lantheus's new formulation of its F18 PSMA-targeted PET imaging agent, now named PYLARIFY TruVu, on the PDUFA date of March 6, 2026. This is a known outcome, making the probability of approval 1. The application was submitted through the 505(b)(2) pathway, leveraging existing clinical data from the OSPREY and CONDOR studies for the original PYLARIFY, which streamlined the review process. The new formulation offers the same diagnostic properties but is designed for enhanced stability at higher radioactive concentrations. This improvement is expected to increase manufacturing batch sizes by approximately 50%, thereby expanding patient access and strengthening the supply chain. Given that the decision has already been made and publicly announced by the company, confidence in an approved outcome is absolute.

Lantheus Holdings Inc. has a strong regulatory track record in the diagnostic radiopharmaceutical space, most notably with their successful approval of PYLARIFY (piflufolastat F18) in May 2021, which became a commercial blockbuster in PSMA-targeted PET imaging. This new F18 formulation likely represents an enhancement or next-generation version of their existing PSMA imaging technology, building on proven clinical foundations. The fact that this formulation has already received approval in other countries provides substantial validation of its safety and efficacy profile, suggesting robust clinical data supporting the application. The diagnostic imaging oncology space, particularly for prostate cancer, represents a significant unmet medical need. PSMA PET imaging has demonstrated superior sensitivity over conventional imaging methods for detecting metastatic lesions, and the FDA has been supportive of advancing diagnostic tools that improve cancer staging and treatment planning. The competitive landscape includes Novartis's LOCAMETZ (Ga-68 PSMA-11), but F18-based agents offer logistical advantages including longer half-life enabling broader distribution networks. Lantheus's manufacturing expertise and established distribution infrastructure for radiopharmaceuticals reduce execution risk concerns. The NDA pathway historically shows approximately 85% approval rates, and diagnostic agents generally face a more favorable risk-benefit assessment compared to therapeutics. Given the company's domain expertise, existing market presence, international regulatory validation, and the clinical utility of PSMA imaging in prostate cancer management, approval appears highly probable pending no unforeseen manufacturing or safety signal issues.

This is a new formulation of an F18 PSMA-targeted PET imaging agent for prostate cancer detection. PSMA PET imaging is a well-established, FDA-approved modality with demonstrated clinical utility in identifying PSMA-positive lesions. Lantheus Holdings has prior experience with diagnostic imaging agents, suggesting regulatory familiarity with their development processes. New formulations of approved imaging agents typically face higher approval odds than novel molecular entities, as the core technology has already been validated. The indication addresses a clear clinical need in prostate cancer staging. Assuming adequate Phase III data showing comparable efficacy and safety to existing PSMA PET agents, approval is highly probable. The main uncertainty lies in whether the formulation offers meaningful advantages over current standards. Given the established regulatory pathway and clinical need, intrinsic approval probability is estimated at approximately 88%.

This is a new formulation of F18, an already approved PSMA-targeted PET imaging agent for prostate cancer. The original F18 (Pylarify) demonstrated strong clinical utility and safety. Reformulations typically face lower regulatory hurdles if they maintain efficacy while improving stability, delivery, or manufacturing. The NDA pathway is appropriate. Given the established clinical need and Lantheus' experience with radiopharmaceuticals, approval is highly likely with potential minor labeling or manufacturing conditions.

The FDA's historical approval rate for NDAs is approximately 85%, which already favors approval, and this rises to ~95% for supplemental applications like new formulations, as this appears to be (despite listed as NDA). Lantheus Holdings Inc. has a strong regulatory track record, having secured FDA approval for PYLARIFY (F-18 piflufolastat), their PSMA-targeted PET agent, in May 2021 under Priority Review for prostate cancer imaging. This prior success demonstrates the company's expertise in radiopharmaceutical manufacturing and clinical data generation, with no major Complete Response Letters (CRLs) or rejections in this space. The new formulation likely addresses practical limitations of F-18 agents, such as short half-life (~110 minutes) or distribution challenges, building on proven safety and efficacy profiles from pivotal trials like CONDOR and OSPREY, which showed high sensitivity/specificity (>80-90%) for detecting PSMA-positive lesions in biochemical recurrence and high-risk prostate cancer. In the therapeutic area of diagnostic oncology imaging, there is significant unmet need for advanced PSMA PET agents to improve staging, biopsy guidance, and therapy selection in prostate cancer, affecting ~1.4 million new cases annually worldwide. Despite a competitive landscape with approved agents like Illuccix (Telix, 2021), Locametz (Novartis, 2023), and Posluma (Blue Earth Diagnostics, 2023), the market is expanding rapidly (projected >$2B by 2028), and new formulations gain approval by demonstrating bioequivalence or manufacturing improvements without new safety signals. Prior approvals in other countries further de-risks the application, signaling robust global data. No known safety concerns (e.g., radiation dosimetry similar to approved peers) or efficacy shortfalls are evident, as F-18 PSMA agents have consistently met endpoints in diverse populations. Thus, FDA is likely to approve to enhance supply chain reliability and patient access.

This NDA involves a new formulation of an F18 PSMA-targeted PET imaging agent for prostate cancer, submitted by Lantheus, an established leader in radiopharmaceutical diagnostics. The parent compound has a well-characterized safety and efficacy profile, significantly de-risking the regulatory pathway. For imaging agents, the FDA approval bar focuses on diagnostic accuracy and safety rather than clinical outcomes, which generally results in higher approval rates compared to therapeutic drugs. The absence of reported Complete Response Letters or advisory committee meetings suggests no major deficiencies were identified during the review. Additionally, the five-day post-PDUFA timeline with no negative news strongly implies a favorable outcome, as FDA typically announces delays or rejections promptly. The high probability reflects the low regulatory risk inherent to diagnostic imaging reformulations and the sponsor's proven track record in this therapeutic area.

This is a new formulation of an already-approved F18 PSMA-targeted PET imaging agent for prostate cancer. Lantheus has extensive experience with PSMA imaging agents (Pylarify approved 2021). New formulations of approved drugs with established safety/efficacy profiles face lower regulatory hurdles. The PDUFA date passed 5 days ago without announced rejection, suggesting potential approval delay or unannounced approval. No red flags in drug status. Imaging agents for prostate cancer have well-established clinical utility and regulatory precedent.

On March 6, 2026, the US Food and Drug Administration (FDA) officially approved Pylarify TruVu (piflufolastat F 18) injection. This is a new formulation of Lantheus Holdings' widely used F 18 prostate-specific membrane antigen (PSMA) targeted PET imaging agent, designed to identify the presence or absence of PSMA-positive lesions in men with prostate cancer. The approval covers patients with suspected metastasis who are candidates for initial definitive therapy, as well as those with suspected recurrence based on an elevated serum PSA level. The application was reviewed under the 505(b)(2) regulatory pathway, leveraging data from the pivotal OSPREY and CONDOR studies that originally supported Pylarify's 2021 approval. Pylarify TruVu was developed to enhance product stability at higher radioactive concentrations, thereby allowing for larger batch sizes—approximately a 50% increase in capacity—and improved distribution efficiency to meet growing clinical demand. With the formal FDA approval already publicly announced and confirmed by multiple reliable sources on the target PDUFA date of March 6, 2026, the regulatory event has definitively resolved. Consequently, the intrinsic probability of approval is strictly 100%. The market pricing should perfectly reflect a resolved status, presenting absolute certainty of a positive outcome.

The PDUFA date has passed, suggesting the FDA has completed its review. The drug is a new formulation of an existing product by an established company, which typically has a more straightforward approval process. However, without explicit clinical trial results or FDA comments, this forecast assumes a favorable review based on the information provided.